Regional anesthesia

The postoperative analgesic efficacy of liposomal bupivacaine versus long-acting local anaesthetics for peripheral nerve and field blocks: A systematic review and meta-analysis, with trial sequential analysis

Eur J AnaesthesiolPublished Systematic review and meta-analysis of randomised trials

Pooled resultResult — go to the resultMean difference −0.9 95% CI −1.4 to −0.4

Authors' conclusion

There is moderate level evidence that liposomal bupivacaine reduces rest pain scores by 0.9 out of 10 units, when compared with long-acting local anaesthetics at 24 hours after surgery, and by 0.7 up to 72 hours after surgery.

Study context

Population
Patients receiving peripheral nerve and field blocks after all types of surgery
Participants
2,122 patients · 27 RCTs
Comparison
Liposomal bupivacaine vs Long-acting local anaesthetics
Outcome
Rest pain score (analogue scale 0 to 10)
Follow-up
24 h
Methodological detailstrial sequential analysis, Quality of evidence moderate
  • Trial sequential analysis
  • Quality of evidence moderate

Pooled result

As reported in the abstract

Mean difference

−0.9

95% CI −1.4 to −0.4

P < 0.001

Liposomal bupivacaine vs Long-acting local anaesthetics
mean difference −0.9 (95% CI −1.4 to −0.4); P < 0.001

Further pooled results

OutcomeMean difference (95% CI)P value
Rest pain score · 48 hI2 = 82%−0.7 (−1.1 to −0.3)P = 0.001
Rest pain score · up to 72 hI2 = 80%−0.7 (−1.1 to −0.3)P < 0.001

Interval morphine consumption · 24, 48 and 72 h

No differences at 24 h
P = 0.15
No differences at 48 h
P = 0.15
No differences at 72 h
P = 0.07

Original publication

The postoperative analgesic efficacy of liposomal bupivacaine versus long-acting local anaesthetics for peripheral nerve and field blocks: A systematic review and meta-analysis, with trial sequential analysis. Eur J Anaesthesiol. Published 10 April 2023. doi:10.1097/eja.0000000000001833

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.